Seventeen control patients with noninfectious medical conditions (including gastrointestinal (GI) bleeding, myocardial infarction, pulmonary embolism, hypertensive urgency, ketoacidosis, arrhythmia, or COPD) were included after written, informed consent (Table 1).
The serum S100β levels of the single patient who had postoperative CT scan evidence of infarction were significantly higher in the immediate postoperative (p = 0.019, 95% CI -0.342 to -0.034) and 24-hour (p = 0.009, 95% CI -0.3 to -0.048) postoperative measurements when compared with patients who had no CT scan evidence of bleeding or infarction.
The health states represent the most frequent and severe adverse events: dyspepsia; symptomatic ulcer; complicated gastrointestinal perforation, ulcer, or bleed; myocardial infarction; stroke; and heart failure.
Quality adjusted life year scores were calculated from pooled estimates of efficacy and major adverse events (that is, dyspepsia; symptomatic ulcer; complicated gastrointestinal perforation, ulcer, or bleed; myocardial infarction; stroke; and heart failure).
Head magnetic resonance imaging showed no infarction, bleeding, or infected arterial aneurysm.
Four adverse events were examined: all-cause mortality, incident myocardial infarction, bleeding, and incident stroke.
Clinical complications such as pulmonary edema and/or heart failure, acute myocardial infarction, bleeding, thrombosis, fistula and acute renal failure were monitored.
In a recent Medicare analysis (N=146 942), bevacizumab and ranibizumab were not associated with increased risks of mortality, myocardial infarction, bleeding or stroke compared with photodynamic therapy or pegaptanib.
Curtis LH, Hammill BG, Schulman KA, Cousins SW (2010) Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration.
